Noncanonical NF-κB pathway involves the processing of p100 to NF-κB2/p52 and prostate cancer cells chronically treated with Enzalutamide have been shown to display higher levels of NF-κB2/p52. The gene discussed is NFKB1; the disease is prostate carcinoma.